ZYDUS HLTHCARE
GenericsZYDUS HLTHCARE is a generic drug manufacturer focused on Infectious Disease, Gastroenterology.
ZYDUS HLTHCARE at a Glance
- Growing R&D activity with 5 trials in last 2 years
- Fast trial execution (32 months median completion)
ZYDUS HLTHCARE's Key Drugs
ZYDUS HLTHCARE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
ZYDUS HLTHCARE's Recent FDA Approvals
ZYDUS HLTHCARE secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ZYDUS HLTHCARE's Therapeutic Areas
ZYDUS HLTHCARE's approved drugs and pipeline span 2 therapeutic areas, led by Infectious Disease and Gastroenterology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ZYDUS HLTHCARE's Top Competitors
ZYDUS HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ZYDUS HLTHCARE Pipeline Snapshot
Active clinical trials for ZYDUS HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/3 completed
- • Speed: 32 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2000-03-16
- Latest
- 2021-11-24
- Applications
- 4
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges